- What Article 2(6) actually says
- Two exemptions, not one: Article 2(6) vs Article 2(8)
- Where the research exemption stops applying
- Frequently asked questions
- What this means for research institutions and publishers
- Looking ahead
A run of academic literature published since mid-2025 — an editorial in GRUR International, a peer-reviewed analysis in Nature’s npj Digital Medicine, and a widely cited Swedish doctoral paper — has converged on the same conclusion: the EU AI Act research exemption is far narrower, and far less certain, than most research offices assume. Regulation (EU) 2024/1689 does carve scientific research and development out of scope, but that carve-out is built from two separate provisions with different wording, different triggers, and different failure points. For institutions running AI-assisted studies, clinical trials, or general-purpose model development, misreading where the exemption ends is now a live compliance risk.
What Article 2(6) actually says
Article 2(6) of the AI Act states that the Regulation “does not apply to AI systems or AI models, including their output, specifically developed and put into service for the sole purpose of scientific research and development.” Two conditions must both be met: the system or model must be developed for scientific research, and it must be put into service — first used for its intended purpose — exclusively for that research. Recital 25 is the only interpretive gloss the legislative text offers, and it does not define “scientific research and development” further.
Critically, Article 2(6) exempts systems that are put into service for research, but it does not extend to systems that are placed on the market. That distinction — put into service versus placed on the market, defined respectively in Articles 3(10) and 3(9) — is where the exemption’s practical limits begin.
Two exemptions, not one: Article 2(6) vs Article 2(8)
Law professor Michèle Finck’s October 2025 editorial “In Search of the Lost Research Exemption” (GRUR International, Vol. 74, Issue 10) makes the point that is most often missed: the AI Act contains two distinct research exemptions, not one. Article 2(6) is narrow and limited to scientific research; Article 2(8) is broader and covers any research, testing or development activity, scientific or not, but only up to the point of market placement or service.
| Provision | What it exempts | Key limit |
|---|---|---|
| Article 2(6) | AI systems/models developed and put into service solely for scientific research and development | Not limited to pre-market stage, but strictly tied to “sole purpose” of research — loses protection once put into service for any other use |
| Article 2(8) | Any research, testing or development activity (not limited to science) regarding AI systems or models | Applies only prior to placing on the market or putting into service; explicitly excludes real-world testing |
Finck argues that this dual structure creates an “interpretative conundrum”: if Article 2(8) only ever covers activity that happens before market placement, and market placement is already the trigger for the Act’s obligations regardless of the exemption, the provision risks adding little independent legal value — precisely the ambiguity that gives the “lost” exemption its name.
Where the research exemption stops applying
The Nature-published analysis by Meszaros and colleagues (npj Digital Medicine, 2026) sets out a conceptual framework built around a single regulatory threshold: placement on the market or putting into service. Everything on the research side of that line can be exempt; everything on the other side is regulated. Three scenarios repeatedly cross that line.
Commercialisation and dual-purpose systems
A system loses its exemption the moment it is not developed for the sole purpose of research. Finck highlights that Horizon Europe-style collaborations, where a university partners with an industrial co-investigator who intends to commercialise the output once the exploratory phase ends, sit in exactly this grey zone. Whether “commercial purpose” is assessed objectively (does a commercial partner exist) or subjectively (did the researchers intend commercialisation) remains unresolved in the text itself.
Post-market deployment and real-world testing
Article 2(8) states plainly that “testing in real-world conditions shall not be covered by that exclusion.” A model tested only in a closed lab environment can remain exempt; the same model tested on live users, patients, or public-facing systems generally cannot, unless it proceeds through the Act’s dedicated real-world testing and regulatory sandbox framework (Articles 57–61). Colonna’s 2024 analysis for the DiVA repository similarly stresses that the exemption was never intended to cover deployment-stage activity dressed up as “ongoing research.”
GPAI models and systemic-risk obligations
Because Article 2(6) explicitly names “AI models” alongside “AI systems,” a general-purpose AI (GPAI) model built and used solely for research is exempt. That exemption evaporates once a provider places the model on the Union market — including releasing a checkpoint for downstream use beyond pure research. From that point, Title VIII’s GPAI obligations under Article 53 (technical documentation, copyright-compliance summaries) apply, and models presumed to carry systemic risk — those trained with cumulative compute above 10^25 FLOPs — face the additional Article 55 duties regardless of open-source licensing. A separate, unconditional exclusion exists for military, defence and national-security AI under Article 2(3); that provision is absolute and is not contingent on “sole purpose,” unlike the research exemptions.
Frequently asked questions
What is Article 2(6) of the EU AI Act?
Article 2(6) excludes AI systems and AI models — including their output — from the AI Act when they are specifically developed and put into service for the sole purpose of scientific research and development. It does not, however, exempt systems that have been placed on the market.
Does the AI Act research exemption cover real-world testing?
No. Article 2(8) states explicitly that testing in real-world conditions is not covered by the research exclusion. Researchers deploying systems outside a controlled setting generally need to use the Act’s regulatory sandbox and real-world testing framework instead.
Are GPAI models exempt from the AI Act during research?
Yes, while a general-purpose AI model is developed and used solely for research it falls outside scope. Once placed on the market, Title VIII obligations attach, with stricter Article 55 duties for models presumed to carry systemic risk above the 10^25 FLOPs training-compute threshold.
Can university-industry collaborations rely on the research exemption?
Only where the sole purpose remains scientific research. Per Finck’s 2025 analysis, Horizon Europe-style projects involving a commercial partner intending future exploitation risk losing Article 2(6)/2(8) protection once a profit-oriented purpose is established.
What this means for research institutions and publishers
Research administration offices — the ARMA, EARMA and INORMS community that oversees institutional compliance — now have a practical due-diligence question to add to AI-enabled research proposals: at what point does this project’s AI system move from “developed for research” to “put into service” or “placed on the market”? That question matters most for:
- Clinical and biomedical AI tools that progress from retrospective lab validation to prospective real-world testing on patients.
- Multi-partner Horizon Europe consortia where an industrial partner holds commercialisation rights from the outset.
- Open-source model releases on code and model-sharing platforms, which several commentators — including the arXiv paper “Beware! The AI Act Can Also Apply to Your AI Research” — flag as a possible trigger for “placing on the market.”
- Foundational research (for example, in AI explainability or causal reasoning) whose downstream applications are not yet known at the outset, which Finck notes may struggle to meet the “sole purpose” test even where no commercial partner is currently involved.
Institutions with dedicated research administration functions are best placed to build this threshold assessment into ethics review and grant-agreement workflows now, rather than retrofitting compliance once a system reaches deployment.
Looking ahead
The AI Act’s general provisions, including Article 2’s scope rules, have applied since 2 February 2025; GPAI obligations followed on 2 August 2025; most remaining obligations, including high-risk system requirements under Annex III, become applicable from 2 August 2026. Every commentator reviewed here — Finck, Meszaros et al., and Colonna — reaches the same practical conclusion: the European Commission’s promised guidance on the research exemptions has not yet resolved the “sole purpose,” commercial-intent, and real-world-testing ambiguities in the text. Until that guidance lands, institutions should treat the exemption as a narrow, conditional safe harbour rather than a blanket shield, and document the specific research purpose, funding structure, and deployment plan for every AI system that currently relies on it.